GlassScriptPhysician profile
Sharon Odum
NPI 1164415949
$1,019.47
in general payments reported to CMS, 2019-2025
20 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.82 · 2023: $242 · 2024: $318 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $174.31 | 2024-2025 | Fanapt |
| Abbvie INC. | $126.23 | 2023-2025 | |
| Exact Sciences Corporation | $107.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $95.26 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $85.55 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $55.39 | 2023-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $44.95 | 2023-2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $33.47 | 2024 | Horizant |
| Astrazeneca Pharmaceuticals LP | $32.23 | 2025 | Breztri, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $32.04 | 2025 | Cobenfy |
| Nestle Healthcare Nutrition INC. | $31.65 | 2023 | |
| Lilly USA, LLC | $29.34 | 2021-2024 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $28.20 | 2023-2024 | Veklury |
| Abbott Laboratories | $24.31 | 2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $23.82 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $22.58 | 2023 | Ingrezza |
| Ucb, INC. | $20.88 | 2023 | Nayzilam |
| Lundbeck LLC | $19.86 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.01 | 2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Odum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.